FINK DENSFORD InVivo TherapeuticsInVivo Therapeutics (NSDQ:NVIV) said today 4th patient in the Inspire study of its Neuro-Spinal Scaffold has improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury. The Cambridge, Mass.-based company’s neuro-spinal scaffold is surgically implanted following acute spinal cord injuries to act as a physical substrate for nerve sprouting…